A cost minimisation analysis of navelbine-cisplatin versus gemcitabine-cisplatin in advanced nonsmall cell lung cancer in Poland

被引：0
|
作者：
Skowron, A. [1 ]
Polak, S. [1 ]
Brandys, J. [1 ]
机构：
[1] Jagiellonian Univ, Krakow, Malopolska, Poland
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63461-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [41] A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels:: A phase II randomized trial
    Rinaldi, M
    Crinò, L
    Scagliotti, GV
    Mosconi, AM
    De Marinis, F
    Gridelli, C
    Selvaggi, G
    Della Giulia, M
    Darwish, S
    Porrozzi, S
    Novello, S
    Cipri, A
    Bartolucci, R
    Calandri, C
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 (10) : 1295 - 1300
  • [42] Cisplatin, vindesine, mitomycin (MVP) vs cisplatin, ifosfamide, navelbine (PIN) vs carboplatin, navelbine (CAN) in advanced non-small cell lung cancer (NSCLC)
    Baldini, E
    Portalone, L
    DeMarinis, F
    Barbera, S
    Ardizzoni, A
    Pennucci, MC
    Raimondi, M
    Conte, PF
    Salvati, F
    Cafferata, MA
    Soresi, E
    Porcile, GF
    Testore, F
    Rimoldi, R
    Bandera, M
    DiRosa, T
    Rinaldi, M
    Lionetto, R
    Rosso, R
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1059 - 1059
  • [43] Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis
    Zheng, Ting
    Jin, Jianjiang
    Zhou, Li
    Zhang, Yuefeng
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (09) : 460 - 468
  • [44] Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey
    Balcik, Pinar Yalcin
    Sahin, Bayram
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (01) : 152 - 158
  • [45] Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)
    Scagliotti, G
    Crino, L
    Conte, PF
    Rinaldi, M
    De Marinis, F
    Gridelli, C
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [46] INDIRECT COMPARISON OF EFFICACY, SAFETY, AND COST: PEMETREXED/CISPLATIN VERSUS BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Orlando, Mauro
    Barraclough, Helen
    Orlov, Sergey
    Rajan, Narayan
    Davey, Peter
    Kanivets, Yana
    Han, Baoguang
    Brnabic, Alan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1232 - S1233
  • [47] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [48] A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
    Tsukiyama I.
    Ejiri M.
    Yamamoto Y.
    Nakao H.
    Yoneda M.
    Matsuura K.
    Arakawa I.
    Saito H.
    Inoue T.
    Journal of Gastrointestinal Cancer, 2017, 48 (4) : 326 - 332
  • [49] RADIATION AND SIMULTANEOUS CISPLATIN IN NONSMALL CELL LUNG-CANCER
    BONOMI, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03): : 739 - 746
  • [50] MITOMYCIN, IFOSFAMIDE, AND CISPLATIN IN NONSMALL CELL LUNG-CANCER
    CULLEN, MH
    ONCOLOGY, 1993, 50 : 31 - 34
12345